HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morris, B. Articles by Dhillon, B. Search for Related Content PubMed PubMed Citation Articles by Morris, B. Articles by Dhillon, B.

Age-related macular degeneration and recent developments: new hope for old eyes?

Princess Alexandra Eye Pavilion, Edinburgh, UK

Correspondence to:
Correspondence to:
Dr Brid Morris
Princess Alexandra Eye Pavilion, Chalmers St., Edinburgh EH3 9HA, UK;bridcmorris{at}yahoo.com

Age-related macular degeneration (AMD) is the commonest cause of blindness in the population over 60 years of age and accounts for over 50% of those registered blind in the UK. The incidence is increasing and as older generations live longer a growing number of patients will be affected in the future. Affected patients lose central vision, important in all aspects of everyday life. This review outlines risk factors for AMD, clinical features, treatment and management strategies for patients, families and physicians caring for those with AMD. Recent trials are included along with practical clinical advice. While there is no curative treatment at present, intervention can reduce the risk of developing AMD and limit disease progression if it occurs. These modalities are discussed here. As new discoveries in the field of genetics and novel therapies emerge, a brighter future seems certain for the ageing population.

Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascular membrane; IOL, intraocular lens; PDT, photodynamic therapy; RNIB, Royal National Institute for the Blind; VEGF, vascular endothelial derived growth factor

Keywords: age-related macular degeneration; blindness; choroidal neovascular membrane; elderly; photodynamic therapy; quality of life

This article has been cited by other articles:

				P Cackett, W T Tay, T Aung, J J Wang, A Shankar, S M Saw, P Mitchell, and T Y Wong Education, socio-economic status and age-related macular degeneration in Asians: the Singapore Malay Eye Study Br. J. Ophthalmol., October 1, 2008; 92(10): 1312 - 1315. [Abstract] [Full Text] [PDF]

				B. G. Short Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations Toxicol Pathol, January 1, 2008; 36(1): 49 - 62. [Abstract] [Full Text] [PDF]

				T. Nagai, H. Imai, S. Honda, and A. Negi Antiangiogenic Effects of Bisphosphonates on Laser-Induced Choroidal Neovascularization in Mice Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5716 - 5721. [Abstract] [Full Text] [PDF]